Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of SAR153191 in ankylosing spondylitis
NL-OMON34640Phase 2Not yet recruiting
- Sponsor
- Sanofi
- Start
- Jul 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sarilumab in ankylosing spondylitis (AS), sponsored by Sanofi. Primary endpoint: Long-term safety of SAR153191. Planned start Jul 2010; status: not yet recruiting.
02
Drugs
sarilumab
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NL-OMON34640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34640.